BPC-157 Dosage Guide: Published Protocols, Timing, and What the Evidence Actually Shows

Legal status: BPC-157 is currently on the FDA Category 2 banned list as of May 2026. It cannot be legally compounded or dispensed by US pharmacies. It is scheduled for PCAC review in July 2026 and may be reclassified.

Evidence level: BPC-157 has strong animal evidence (100+ published studies) but very limited human clinical data. Most dosing information is extrapolated from animal research using allometric scaling — a legitimate pharmacological method, but one that produces estimates rather than established doses.

This is not medical advice. This guide consolidates published research and reported clinical practices for educational purposes. It is not a prescription, dosing recommendation, or encouragement to use BPC-157. If BPC-157 becomes available for compounding, dosing decisions should be made with a licensed medical provider who can account for your individual circumstances.

Human trials: The most significant human data comes from a Phase 2 trial of PL 14736 (an oral BPC-157 formulation) in patients with ulcerative colitis. This trial used: - Low dose: 0.4 mcg (microgram) total oral dose - High dose: 0.4 mg (milligram) total oral dose - Duration: 30 days - Both doses showed improvement vs. placebo; the higher dose was more effective

Additional small human studies and case series have been reported at conferences but are not widely published in indexed journals.

Animal studies (typical protocol): - Standard dose: 10 mcg/kg body weight - Route: intraperitoneal (IP) injection or oral in drinking water - Frequency: once daily - Duration: 14-30 days - Some studies use a lower dose of 0.16 mcg/kg as a comparison

Animal doses cannot be directly translated to human doses by simple weight multiplication. Allometric scaling accounts for metabolic rate differences between species.

Allometric scaling converts animal doses to human-equivalent doses (HED) by accounting for differences in body surface area and metabolic rate between species. For rats to humans:

FDA-recommended conversion: HED = Animal dose × (Animal Km ÷ Human Km) - Rat Km = 6.2 - Human Km = 37 - Conversion factor: 6.2 ÷ 37 = 0.162

Applied to BPC-157: - Rat dose: 10 mcg/kg - Human equivalent: 10 × 0.162 = 1.62 mcg/kg - For a 75 kg human: 1.62 × 75 = ~122 mcg/day

However: Many pharmacologists argue this scaling is conservative for peptides, and clinical practice typically uses higher doses (250-500 mcg/day). The rationale is that peptides have short half-lives, rapid clearance, and the therapeutic window may be wider than the strict allometric calculation suggests.

Another common scaling approach (simple body weight proportional) yields: - 10 mcg/kg × 75 kg = 750 mcg/day

The true optimal human dose likely falls somewhere between these estimates — which is exactly why proper clinical trials are needed.

The following are dosing patterns reported by clinicians in published interviews, conference presentations, and clinical practice guidelines — NOT FDA-approved protocols:

Musculoskeletal healing (tendon, ligament, muscle): - Dose: 250-500 mcg per injection - Frequency: Once or twice daily - Route: Subcutaneous injection, ideally near (not into) the injury site - Duration: 4-8 weeks - Some protocols add TB-500 (thymosin beta-4) alongside BPC-157

Gut healing (IBS, leaky gut, post-NSAID damage): - Dose: 250-500 mcg - Frequency: Once or twice daily - Route: Oral (capsule or sublingual) preferred for GI conditions; SubQ also reported - Duration: 4-12 weeks - Often taken on empty stomach 30 minutes before food

General recovery / systemic healing: - Dose: 250-500 mcg once daily - Route: Subcutaneous (abdomen) - Duration: 4-6 weeks - Often cycled: 4 weeks on, 2-4 weeks off

Note on local vs. systemic injection: Animal studies show BPC-157 has systemic effects regardless of injection location. However, some clinicians prefer injecting near the site of injury for theoretical local concentration benefits. The evidence for local vs. distant injection superiority in humans does not exist.

Half-life: BPC-157's exact half-life in humans is not well-established. Estimates from animal pharmacokinetic data suggest it is relatively short (hours, not days), which is why most protocols use daily or twice-daily dosing.

Time of day: No published evidence supports one time of day over another. Common practices include: - Morning injection on empty stomach (for gut-related use) - Injection before bed (theory: healing occurs during sleep) - Split dosing AM/PM for higher daily amounts

Relation to food: For oral BPC-157, most protocols recommend taking it on an empty stomach (30 minutes before meals) to reduce degradation by digestive enzymes. For injectable, food timing is considered less relevant.

Relation to exercise: Some clinicians suggest injecting after exercise rather than before, based on the theory that post-exercise inflammation signals serve as a beneficial stimulus and BPC-157 enhances the subsequent repair phase. This is theoretically plausible but not clinically validated.

Loading protocols: Some providers use a higher initial dose (500 mcg 2x/day for the first 7-10 days) followed by a maintenance dose (250 mcg/day). This "loading" approach has no published evidence base but follows pharmacological logic if the healing response benefits from early high exposure.

Oral BPC-157: - The human ulcerative colitis trial used oral administration successfully - Animal studies consistently show systemic effects from oral dosing - BPC-157 appears more acid-stable than most peptides (it is derived from gastric juice proteins) - Oral is preferred for GI-tract conditions (direct local contact + systemic absorption) - Bioavailability is likely lower than injectable but has not been quantified in humans - Available as capsules or liquid formulations

Injectable BPC-157: - Standard subcutaneous injection (same technique as insulin) - Assumed higher bioavailability than oral - Allows local injection near injury sites - Preferred by most clinicians for musculoskeletal healing - Requires reconstitution from lyophilized powder - Requires refrigerated storage after reconstitution

Which is better? There is no definitive answer because no head-to-head bioavailability study exists in humans. The practical consensus: use oral for gut conditions, injectable for everything else. Some patients use both simultaneously (oral + injectable) though evidence for combination superiority is anecdotal only.

BPC-157 has an unusually clean safety profile in published research:

Animal toxicology: Multiple studies report no observable toxicity at doses up to 100x the standard therapeutic dose. No LD50 (lethal dose) has been identified. No organ toxicity, no behavioral changes, no reproductive effects have been reported in animal models.

Human data: The Phase 2 ulcerative colitis trial reported no serious adverse events attributable to BPC-157 at either dose level. Adverse event rates were comparable to placebo.

Commonly reported side effects in clinical practice: - Mild nausea (more common with oral, usually transient) - Injection site redness/irritation (mild, resolves within hours) - Headache (infrequent, typically first few days only) - Lightheadedness (rare, usually with first dose)

Theoretical concerns (not observed but discussed in literature): - Angiogenesis promotion (BPC-157 upregulates VEGF) — theoretical concern for individuals with active cancers. No evidence BPC-157 promotes cancer growth, but most clinicians avoid use in active malignancy as a precaution. - Growth factor stimulation in general — similar precautionary avoidance during active infections or inflammatory conditions where new blood vessel growth could be problematic.

Bottom line: BPC-157 appears remarkably safe in available data. However, "absence of evidence is not evidence of absence" — the total amount of human safety data is small, and long-term effects are unknown.

BPC-157 is one of the most researched peptides in animal models and one of the most widely used in clinical practice — yet it lacks the rigorous human dose-finding studies that would establish truly evidence-based dosing guidelines.

What we can say: - Animal studies consistently use 10 mcg/kg with remarkable results - Allometric scaling suggests 120-750 mcg/day for humans depending on the method - Clinical practice has converged on 250-500 mcg/day as the most common protocol - Both oral and injectable routes appear effective - Safety data (limited as it is) shows a wide therapeutic margin - Duration is typically 4-8 weeks with cycling

What we cannot say: - What the optimal human dose actually is (no dose-ranging trials) - Whether injectable is definitively better than oral (no comparison trial) - What the long-term effects of repeated use are (no longitudinal data) - Whether local injection is superior to distant injection (no comparison)

If BPC-157 is reclassified at the July 2026 PCAC meeting, expect clinical trial activity to accelerate rapidly. Until then, any dosing decision should involve a licensed medical provider who can weigh your specific situation.